Lexaria Bioscience Corp.

Overview

Compare with Summit Therapeutics, 4D Pharma or Unicycive Therapeutics, Inc., or pick any stock.

• TickerLEXX on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersKelowna, Canada¹
• Incorporated inNV³
• Business address100 - 740 Mccurdy Road, Kelowna, A1 V1X 2P7³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECH TM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.⁴ From its latest annual report

Corporate structure

Lexaria Bioscience Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Lexaria Bioscience Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

Description of Property

The Company headquarters is in Kelowna, British Columbia Canada in a leased facility with 2,250 square feet of office space to accommodate our finance and administrative functions as well as a Health Canada approved research lab of approximately 1,000 square feet accommodating our in-house research and development team. The current lease has been extended for an additional five years expiring on November 14, 2028. We believe our current facilities are suitable and adequate for the Company’s current operational requirements.

Item 2 of the 10-K filed Nov 28, 2025.⁴

Leadership

Who has led Lexaria Bioscience Corp., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerRichard Christopher Sep 5, 2024 to now¹⁴
• PresidentJohn Martin Docherty Apr 7, 2015 to now¹⁵
• PresidentLeonard Macmillan Jul 14, 2006 to Jul 14, 2006¹⁶
• Chief financial officerNelson Cabatuan Mar 15, 2024 to Mar 15, 2024¹⁷
• Chief financial officerMichael Elliot Shankman Oct 2, 2024 to now¹⁸
• Chief financial officerGregory Downey Apr 16, 2021 to Oct 18, 2022¹⁹
• Chief financial officerAllan Horst Spissinger Jun 8, 2017 to Apr 23, 2020²⁰
• Chief financial officerBaljinder Bhullar May 20, 2009 to Dec 16, 2015²¹
• Chief financial officerDiane Rees Jul 14, 2006 to Jul 14, 2006²²

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorChristopher Bunka named Dec 20, 2021 to Sep 21, 2026³⁵
• DirectorTED MCKECHNIE named Dec 20, 2021 to Oct 16, 2024³⁶

Former names

• Lexaria Corp.Mar 3, 2008 to May 11, 2016³

Timeline

1. Sep 9, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure³⁷
2. Sep 1, 20268-K Other events³⁸
3. Aug 17, 20268-K Other events³⁹
4. Aug 10, 20268-K Listing notice or transfer⁴⁰
5. Jul 30, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed⁴¹
6. Feb 6, 20268-K Listing notice or transfer⁴²
7. Jan 28, 20268-K Shareholder vote⁴³
8. Dec 16, 20258-K Entered a material agreement; Unregistered sale of shares; Other events⁴⁴
9. Sep 29, 20258-K Entered a material agreement; Unregistered sale of shares; Other events⁴⁵
10. Sep 25, 20258-K Ended a material agreement⁴⁶
11. Jun 12, 20258-K Entered a material agreement⁴⁷
12. Apr 28, 20258-K Entered a material agreement; Unregistered sale of shares; Other events⁴⁸
13. Sep 5, 2024New chief executive Richard Christopher becomes CEO¹⁴

Calendar

Coming up

1. Nov 25, 2026Reports results for the quarter ending Aug/2026 A year earlier it reported ($1.95) a share, on Nov 26, 2025.⁴⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

257 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 64 major events, 63 insider forms, 10 large holders, 8 private raises, 90 other. The latest 20:

1. Oct 13, 2026EFFECT EDGAR
2. Oct 13, 2026424B3 424 B3 EDGAR
3. Oct 2, 2026S-3 EDGAR
4. Sep 21, 2026D EDGAR
5. Sep 9, 20268-K EDGAR
6. Sep 1, 20268-K EDGAR
7. Aug 17, 20268-K EDGAR
8. Aug 10, 20268-K EDGAR
9. Jul 30, 20268-K EDGAR
10. Jul 13, 202610-Q EDGAR
11. Apr 13, 202610-Q EDGAR
12. Mar 18, 20264 PRIMARY DOCUMENT EDGAR
13. Feb 6, 20268-K EDGAR
14. Jan 28, 20268-K EDGAR
15. Jan 28, 2026S-8 EDGAR
16. Jan 14, 2026EFFECT EDGAR
17. Jan 14, 2026424B3 EDGAR
18. Jan 14, 202625-NSE EDGAR
19. Jan 13, 202610-Q EDGAR
20. Dec 29, 2025S-3 FORM S-1 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

14 open-market trades by officers, directors and large owners since October 2021: 13 buys and 1 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Invenomic Capital Management LPSC 13G/A, 4 filings Feb 14, 2022 to Nov 14, 2024⁵⁰
• Wayne W. BoosSC 13D/A, 5 filings Sep 18, 2023 to Sep 23, 2024⁵¹
• L1 Capital Global Opportunities Master Fund, Ltd.SC 13G/A, 1 filing Feb 14, 2022⁵²

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Sep 9, 2026Raised $113,492 in a private offering of securities³⁵ Form D: 3 investors so far Form D
2. Dec 16, 2025Raised $3.5 million in a private offering of securities⁵³ Form D: 5 investors so far Form D
3. Sep 29, 2025Raised $4 million in a private offering of securities⁵⁴ Form D: 5 investors so far Form D
4. Oct 16, 2024Raised $5 million in a private offering of securities³⁶ Form D: 1 investor so far Form D
5. Apr 30, 2024Raised $364,629 in a private offering of securities⁵⁵ Form D: 1 investor so far Form D
6. Feb 16, 2024Raised $3.6 million in a private offering of securities⁵⁶ Form D: 2 investors so far Form D
7. Oct 3, 2023Raised $1.6 million in a private offering of securities⁵⁷ Form D: 1 investor so far Form D
8. Dec 16, 2021Raised $1.2 million in a private offering of equity⁵⁸ Form D: 1 investor so far Form D

SEC filer profile

How Lexaria Bioscience Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARLexaria Bioscience Corp.¹
• CIK0001348362
• Employer ID (EIN)20-2000871⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inNevada⁴
• Fiscal year endsAugust 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address100 - 740 Mccurdy Road, Kelowna, A1 V1X 2P7¹
• Phone250-765-6424¹
• Shares outstanding24,787,446 as of Jul 13, 2026¹³
• Public float$24.6M as of Feb 28, 2025⁴
• AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceMar 1, 2006¹
• Filings1,098 in all: 4 (395), 8-K (378), 10-Q (55), EFFECT (25), CORRESP (20), 10-K (17), 3 (16), DEF 14A (16)¹
  All 47 form types

  424B3 (15), D (15), UPLOAD (15), SC 13D/A (12), 4/A (9), 424B5 (9), POS AM (9), S-1 (9), S-8 (8), PRE 14A (7), 10-K/A (6), 10QSB (6), S-1/A (6), S-3 (5), SC 13G/A (4), 10-Q/A (3), 424B4 (3), 8-K/A (3), SB-2/A (3), SC 13D (3), 10KSB (2), 10KSB/A (2), CT ORDER (2), DEFA14A (2), S-4/A (2), SB-2 (2), SC 13G (2), 10-KT (1), 25-NSE (1), 8-A12B (1), 8-A12G (1), CERT (1), DEF 14C (1), DRS (1), NT 10-K (1), NTN 10K (1), RW (1), S-1MEF (1), S-4 (1)

• Latest filingsAnnual report (10-K) Nov 28, 2025
  Quarterly report (10-Q) Jul 13, 2026
  Proxy statement (DEF 14A) Dec 10, 2025
  Latest 8-K (8-K) Sep 9, 2026

Securities registered for trading

From the cover page of the 10-K filed Nov 28, 2025 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Lexaria Bioscience Corp. names in Item 1A of its 10-K filed Nov 28, 2025: 27 risks under these headings, as written.⁴

• A. Risks Associated with our Business and Industry
• DehydraTECH-enabled pharmaceutical products may not successfully proceed to commercialization.
• If we are unable to retain and hire qualified personnel, we may not be able to implement our business plan successfully.
• We face substantial competition, which may result in others discovering, developing and/or commercializing technology or products similar to ours before or more successfully than us.
• Any failure in protecting our intellectual property may have a negative impact on our ability to develop and license DehydraTECH.
• Technological R&D in the bioscience industry involves a lengthy, expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete our studies or trials.
• If we are unable to obtain and maintain sufficient patent protection, or if the scope of the patent protection is not sufficiently broad, our competitors could develop technology similar to ours.
• We are dependent on the services of third parties and unsatisfactory performance will negatively affect our Company.
• Any failure to prevent or mitigate security breaches and improper access to or disclosure of our data or our user data could result in the loss or misuse of such data, which could harm our business and reputation and diminish our competitive position.
• We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed alleged trade secrets.
• B. Risks Associated with our Financial Condition
• There is substantial doubt as to our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail or cease our operations.

Legal proceedings

We are not party to any material, pending or existing legal proceedings against our Company or its subsidiaries nor are we involved as a plaintiff in any other material proceeding or pending litigation. There are no other proceedings in which any of our directors, executive officers, or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to Lexaria or any of its subsidiaries.

The opening of Item 3, Legal Proceedings.⁴